Orchid Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 2,205.91 million compared to INR 1,597.6 million a year ago. Revenue was INR 2,282.07 million compared to INR 1,686.91 million a year ago. Net income was INR 294.31 million compared to INR 75.87 million a year ago. Basic earnings per share from continuing operations was INR 6.18 compared to INR 1.86 a year ago. Diluted earnings per share from continuing operations was INR 6.18 compared to INR 1.86 a year ago. Basic earnings per share was INR 6.18 compared to INR 1.86 a year ago. Diluted earnings per share was INR 6.18 compared to INR 1.86 a year ago.
For the nine months, sales was INR 6,022.66 million compared to INR 4,559.98 million a year ago. Revenue was INR 6,201.23 million compared to INR 4,736.99 million a year ago. Net income was INR 586.4 million compared to net loss of INR 128.21 million a year ago. Basic earnings per share from continuing operations was INR 12.32 compared to basic loss per share from continuing operations of INR 3.14 a year ago. Diluted earnings per share from continuing operations was INR 12.32 compared to diluted loss per share from continuing operations of INR 3.14 a year ago. Basic earnings per share was INR 12.32 compared to basic loss per share of INR 3.14 a year ago. Diluted earnings per share was INR 12.32 compared to diluted loss per share of INR 3.14 a year ago.